Figure 2
Figure 2. Positive specimens by EBV disease status and test characteristics in plasma or PBMCs. (A) The percentage of patients with EBV DNA detected in plasma only, PBMCs only, or both plasma and PBMCs, separated by whether the patients had active, systemic EBV+ disease, EBV+ disease in remission, or no EBV+ disease. (B) For a range of cutoffs, the sensitivity of plasma (solid line) and PBMC (dashed line) specimens for distinguishing those with active, systemic EBV+ diseases from those with no EBV+ disease. (C) For a range of cutoffs, the specificity of plasma (solid line) and PBMC (dashed line) specimens for distinguishing those with active, systemic EBV+ diseases from those with no EBV+ disease.

Positive specimens by EBV disease status and test characteristics in plasma or PBMCs. (A) The percentage of patients with EBV DNA detected in plasma only, PBMCs only, or both plasma and PBMCs, separated by whether the patients had active, systemic EBV+ disease, EBV+ disease in remission, or no EBV+ disease. (B) For a range of cutoffs, the sensitivity of plasma (solid line) and PBMC (dashed line) specimens for distinguishing those with active, systemic EBV+ diseases from those with no EBV+ disease. (C) For a range of cutoffs, the specificity of plasma (solid line) and PBMC (dashed line) specimens for distinguishing those with active, systemic EBV+ diseases from those with no EBV+ disease.

Close Modal

or Create an Account

Close Modal
Close Modal